Guardant Health, Inc. (GH) News
Filter GH News Items
GH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GH News Highlights
- GH's 30 day story count now stands at 8.
- Over the past 21 days, the trend for GH's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- ALTO, CRC and LAB are the most mentioned tickers in articles about GH.
Latest GH News From Around the Web
Below are the latest news stories about GUARDANT HEALTH INC that investors may wish to consider to help them evaluate GH as an investment opportunity.
Here's Why Guardant Health (GH) Looks Ripe for Bottom FishingGuardant Health (GH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
Insiders pour millions into these 2 stocks — this is what makes them attractive buysAfter January’s stock rally, the story in the markets for the past two months has been volatility. Stocks were on a seesaw even before the recent SVB crash, and the banking woes of the last two weeks have simply exacerbated the up and down swings. The increased uncertainty in the market conditions has put a premium on data analysis, the ability to collect and decipher the mass of information generated by Wall Street’s aggregated trading activity. Fortunately, there are already experts out there |
Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherencePALO ALTO, Calif., March 21, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has announced support for an investigator initiated study led and conducted by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) to evaluate patient compliance with a blood-based test for colorectal cancer (CRC) screening. In this study, The Ohio State University Guardant Shield Colorectal Canc |
In the wake of Guardant Health, Inc.'s (NASDAQ:GH) latest US$536m market cap drop, institutional owners may be forced to take severe actionsKey Insights Institutions' substantial holdings in Guardant Health implies that they have significant influence over... |
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood testPALO ALTO, Calif., March 10, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the final module of its premarket approval (PMA) application for Shield™, Guardant Health’s blood test to screen for colorectal cancer (CRC). |
2 Stocks That Could Rebound and Rise 30% or More in 2023With its shares down by 4.2% in the last 12 months, Zai Lab (NASDAQ: ZLAB) is now poised to surge like wildfire. Thanks to the slew of looming launches of new products, Wall Street analysts have set some aggressive price targets for Zai Lab on average, calling for its price near $40.90 to rise by 98% to reach $81.04 within a year -- and the analysts are probably right. Before 2026, it plans to commercialize up to 11 new therapies, ranging from biologics like Adagrasib for colorectal cancer and non-small cell lung cancer to more exotic interventions, like tumor treating fields (TTFields), which is a therapy based on electromagnetic energy projected from a specialized device. |
How Much Upside is Left in Guardant Health (GH)? Wall Street Analysts Think 75.47%The average of price targets set by Wall Street analysts indicates a potential upside of 75.5% in Guardant Health (GH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
2 Potentially Explosive Growth Stocks Down 30% or More to Buy for the Next Bull MarketEnterprising investors who pay attention to this can set themselves up for future success by buying into great growth stocks while in the hard landing phase of the volatility. Two biopharma stocks are particularly appealing right now as buy candidates before the next bull market has a chance to buoy their shares once again. It develops liquid biopsies for cancer screening, treatment selection, treatment efficacy evaluation, and recurrence detection, which means that patients don't need to experience the invasiveness of a traditional biopsy to get the health information their doctors need to determine a course of treatment. |
Musa Tariq Joins Guardant Health Board of DirectorsPALO ALTO, Calif., February 27, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the appointment of Musa Tariq to its board of directors, effective March 6. Currently the chief marketing officer for GoFundMe, the world’s leading fundraising platform, Tariq is a distinguished marketing executive with experience leading global consumer brands. |
Q4 2022 Guardant Health Inc Earnings CallQ4 2022 Guardant Health Inc Earnings Call |